Sheehan Disability Scale (SDS)

Be confident that you are using the Sheehan Disability Scale (SDS) correctly. Purchase directly from the author and Copyright Holder, Dr. David V Sheehan. Look for the QR code linking to www.dashneuroscience.com to make sure you are using the SDS directly from the Copyright Holder. To get training, consultation, Sheehan Disability Scale interpretation or a guide to Sheehan Disability Scale scoring contact us!

For any scientific questions relating to the SDS, contact David V Sheehan MD MBA directly by email at: davidVsheehan@gmail.com

SDS FAQ View Products by Study Type

About the SDS

The SDS Sheehan Disability Scale PDF* or Paper available.

The Sheehan Disability Scale (SDS) is a short (5-item), easy-to-use 1 page measure of disability and functional impairment. Patients are asked to rate the extent to which their symptoms have disrupted their lives in the last week across 3 separate domains:

Work / Schoolwork
Social life / Leisure activities
Family life / Home responsibilities

SDS
Sheehan Disability Scale

The Sheehan Disability Scale is a short, simple, treatment outcome measure of disability and functional impairment. It can be either patient-rated or clinician-rated but clinician input and judgment are always recommended with making any assessment for it to be valid. Sheehan Disability Scale PDF* or Paper available.

License Agreement

Purchase A Preview

SDS-A (Adolescent)
Sheehan Disability Scale

The Sheehan Disability Scale Adolescent (SDS-A) is a short, simple, treatment outcome measure of disability and functional impairment. The SDS-A is a patient rated version by the adolescent but clinician input and judgment are always recommended with making any assessment for it to be valid. Sheehan Disability Scale PDF* or Paper available.

License Agreement

Purchase A Preview

SDS-P (Pediatric)
Sheehan Disability Scale

The Sheehan Disability Scale Pediatric (SDS-P) is a short, simple, treatment outcome measure of disability and functional impairment. It can be parent or clinician rated but clinician input and judgment are always recommended with making any assessment for it to be valid. Sheehan Disability Scale PDF* or Paper available.

License Agreement

Purchase A Preview

How to LICENSE the sheehan disability scale (sds)

Any use of the SDS requires a license. Get access to knowledge about Sheehan Disability Scale scoring from the author and Sole Copyright Holder of the SDS! Sheehan Disability Scale PDF* or Paper available. Please complete the template license agreement for the specific Sheehan Disability Scale you are requesting by clicking “License Agreement” above. After it is completed in full and signed, please send it to Dr. Sheehan at the email address in the license agreement for review.

COST

The cost of licensing Sheehan Disability Scale is $4 per use. This licensing fee applies to all uses. For customized versions please review the License Agreement template.

TRANSLATIONS

The English language versions of Dr. Sheehan’s scales and structured interviews are distributed directly by Dr. Sheehan and not by MAPI. You are required to get a license from Dr. Sheehan for all the administrations to be done in all languages in your study / clinical setting and to pay the invoice to Dr. Sheehan for this license. If you need a translation beyond the English version, you will need to reach out to MAPI after getting a fully executed license for all the administrations in any language. For more information visit the FAQ page.

Sheehan Disability scale TRAINING

For information about virtual web-based training on the Sheehan Disability Scale (SDS) and Sheehan Disability Scale interpretation please see our FAQ or download our Training Form.

For more information contact: training@harmresearch.org or davidVsheehan@gmail.com.

Training Form

sds FAQ

How to cite the sds

The SDS has been cited over 3,000 times in publications.

Note: The SDS is a clinical decision support tool to measure disability and impairment. The below listed studies validated the SDS under conditions in which it was used with its Discan metric (using graphic, numeric and verbal descriptors) and in which it was rated in paper format as a primary source document. The results cannot be generalized to any other conditions or format. For FDA guidance on CDS or using software in diagnosis: visit the FDA website.

Use the following citations in referencing the SDS:

Sheehan KH; Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. International Clinical Psychopharmacology 2008;23(2):70-83. DOI: http://dx.doi.org/10.1097/YIC.0b013e3282f2b4d6
Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3):89–95. PDF: http://journals.lww.com/intclinpsychopharm/Abstract/1996/06003/The_measurement_of_disability.15.aspx
Leon AC, Shear MK, Portera L, et al: Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 27:78–82, 1992. DOI:http://dx.doi.org/10.1007/BF00788510
Leon AC, Olfson M, Portera L, et al: Assessing impairment in primary care: a psychometric analysis of the Sheehan Disability Scale. Int J Psychiatry Med 27:93–105, 1997. DOI:http://dx.doi.org/10.2190/T8EM-C8YH-373N-1UWD
Olfson M, Kathol RG, Weissman MM, Sheehan DV, Leon AC, Hoven C. Mental Disorders and Disability in a Primary Care Group Practice. American Journal of Psychiatry. 1997; 154: 1734-1740. DOI:http://dx.doi.org/10.1176/ajp.154.12.1734
Sheehan DV, Harnett-Sheehan K. Psychometric Assessment of Anxiety Disorders. Chapter 8 in Anxiety: Psychobiological and Clinical Perspectives (Sartorius N, Andreoli V, Cassano G, Eisenberg L, Kielholz P, Pancheri P, & Racagni G, eds. Hemisphere Publishing Corporation, Washington, DC. 1990; 85-100. ISBN: 1560320648, 9781560320647
Sheehan, D. V. (2000). Sheehan disability scale. Handbook of psychiatric measures, 113-115. ISBN: 0890424152, 9780890424155.
Sheehan DV, Meyers AL, Prakash A, Robinson MJ, Swindle RW, Russell JM, et al. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Current Medical Research and Opinion. 2008; 24(9):2457-66. DOI: http://dx.doi.org/10.1185/03007990802293643
Sheehan, DV, Harnett-Sheehan, K, Spann, M, Thompson, H, Prakash, A. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. International clinical psychopharmacology. 2011;2: 75-83. DOI: http://dx.doi.org/10.1097/YIC.0b013e328341bb5f
Sheehan DV, Chokka PR, Granger RE, Walton RJ, Raskin J, Sagman D. Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine. Human Psychopharmacology: Clinical and Experimental. 2011;26(3):242-51. DOI: http://dx.doi.org/10.1002/hup.1199
Mancini, M, Sheehan DV, Demyttenaere, K, Amore, M, Deberdt, W, Quail, D, Sagman, D. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. International Clinical Psychopharmacology. 2012; 27(6): 298-309. DOI: http://dx.doi.org/10.1097/YIC.0b013e3283589a3f
Sheehan DV, Locklear J, Svedsäter H, Datto C. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. International Clinical Psychopharmacology. 2012;27(5):239-48. DOI: http://dx.doi.org/10.1097/YIC.0b013e328356ac78
Sheehan, DV, Svedsäter, H, Locklear, JC, Eriksson. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): Data from a randomized-withdrawal, placebo-controlled maintenance study. Journal of Affective Disorders. 2013; 151(3): 906-913. DOI: http://dx.doi.org/10.1016/j.jad.2013.07.037

*Looking for the Sheehan Disability Scale PDF: Dr. Sheehan licenses the instrument in paper format for distribution as follows: (1) in paper form for any uses, or (2) in fixed-pdf form, paper form, or both for use in clinical or academic research trials or studies.